Alvotech (ALVOW)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
- Symbol
- ALVOW
- Exchange
- Nasdaq
- Sector
- Manufacturing
- Industry
- Biological Products, (No Diagnostic Substances)
- Market cap
- $115.45M
- 52 week range
- 0.27 - 0.37
Valuation
- Share price
- $0.33 (close of 2026-09-14)
- P/E (TTM)
- 3.70x
- Price to book
- -0.41x
- Price to free cash flow
- -1.01x
- Enterprise value
- $1.39B
- Book value per share
- $-0.91
Price performance
| Period | Change |
|---|
| 1 day | 0.00% |
| All time | 0.00% |
Profitability and growth
- Return on equity
- -9.81%
- Return on invested capital
- 3.94%
- Return on assets
- 1.88%
- Return on capital employed
- 6.61%
- Gross margin
- 59.82%
- Net margin
- 4.76%
- EBITDA margin
- 19.79%
- Revenue growth
- 19.74%
- Net income growth
- 112.04%
- Free cash flow growth
- 60.53%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -99.32%
- Current ratio
- 1.89x
- Net debt to EBITDA
- 4.10x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $586.32M
- Cost of revenue
- $235.56M
- Gross profit
- $350.76M
- EBITDA
- $116.06M
- Net income
- $27.92M
- Earnings per share
- $0.10
- Research and development
- $184.19M
- Interest expense
- $149.19M
- Shares outstanding
- 289.73M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $586.32M | $350.76M | $27.92M | $0.10 |
| 2024-12-31 | $489.68M | $304.37M | $-231.86M | $-0.87 |
| 2023-12-31 | $91.43M | $-69.42M | $-551.73M | $-2.43 |
| 2022-12-31 | $83.03M | $18.93M | $-513.58M | $-2.60 |
| 2021-12-31 | $36.77M | - | $-101.50M | $-0.92 |
| 2020-12-31 | $66.62M | $10.54M | $-170.04M | $-1.82 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 59.82% | 4.76% | -9.81% | 3.94% |
| 2024-12-31 | 62.16% | -47.35% | 56.17% | 7.62% |
| 2023-12-31 | -75.93% | -603.42% | 59.17% | -193.85% |
| 2022-12-31 | 22.80% | -618.55% | 90.99% | -176.96% |
| 2021-12-31 | - | -276.04% | 74.85% | -50.76% |
| 2020-12-31 | 15.81% | -255.26% | 19.61% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $172.36M | $1.26B |
| 2024-12-31 | $51.43M | $1.04B |
| 2023-12-31 | $11.16M | $922.13M |
| 2022-12-31 | $66.43M | $744.65M |
| 2021-12-31 | $17.56M | $398.14M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-114.67M | $7.38M |
| 2024-12-31 | $-290.50M | $7.63M |
| 2023-12-31 | $-345.42M | $18.03M |
| 2022-12-31 | $-350.27M | $10.32M |
| 2021-12-31 | $-248.63M | - |
| 2020-12-31 | $-81.78M | - |
Investor relations
Filings and sources
- Company website
- alvotech.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades